2008

1. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study

   Arthritis and Rheumatism, Vol. 58, Núm. 10, pp. 2968-2980